• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2015: One-year results bear out for Edwards Lifesciences’ Sapien 3 valve, Sapien XT wins FDA PMA

TCT 2015: One-year results bear out for Edwards Lifesciences’ Sapien 3 valve, Sapien XT wins FDA PMA

October 15, 2015 By Brad Perriello

TCT 2015Updated: Added new FDA approval information on the Sapien XT

The low rate of complications seen with the next-generation Sapien 3 replacement heart valve made by Edwards Lifesciences (NYSE:EW) at 30 days persisted for a full year, researchers said today at the annual Transcatheter Cardiovascular Therapies conference in San Francisco.

The company also announced its Sapien XT Transcatheter heart valve won FDA approval at the conference.

One-year data from Irvine, Calif.-based Edwards’ Partner II trial, which enrolled 583 high-risk or inoperable aortic stenosis patients for implantation with the Sapien 3 transcatheter aortic valve implant, showed a follow-up rate at 1 year of 98.6% and an all-cause survival rate of 85.6%. The rate of disabling stokes at 1 year was 2.4%, with no difference between the high-risk and inoperable cohorts, or between devices delivered transfemorally or transapically.

Paravalvular regurgitation rates were 2.7% for moderate regurgitation and 29.1% for mild regurgitation, with no increased mortality in patients with mild regurgitation; there was no incidence of severe regurgitation.

“The combination of new design features, procedural improvements, operator experience, and improved patient selection have all contributed to a low rate of adverse events and a high rate of 1-year survival in TAVI for high-risk and inoperable patients with severe aortic stenosis,” study investigator Dr. Howard Herrmann, of the Perelman School of Medicine at the University of Pennsylvania, said in prepared remarks. “This represents a 50% reduction in mortality in both [high-risk] and [inoperable] patients as compared with the 1st-generation TAVI device.

“This one-year follow-up data support the use of TAVR as the preferred therapy in high-risk and inoperable patients with aortic stenosis,” Herrmann said.

Edwards said its Sapien xT transcatheter heart valve won FDA pre-market approval for aortic valve-in-valve procedures.

“U.S. approval of the valve-in-valve procedure provides an important minimally invasive treatment option for patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valves,” transcatheter heart valves prez Larry Woods said in a press release.

Filed Under: Clinical Trials, Replacement Heart Valves Tagged With: Edwards Lifesciences, TCT 2015

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy